Skip to content

Study · Animal study (in vivo) · rat · 1998

5 results

Brainstem application of melanocortin receptor ligands produces long-lasting effects on feeding and body weight.

Grill HJ, Ginsberg AB, Seeley RJ, Kaplan JM

The Journal of neuroscience : the official journal of the Society for Neuroscience1 Dec 1998Cited by 207 (Europe PMC)

PMID9822766 (opens in a new tab)PMCIDPMC6793290 (opens in a new tab)DOI10.1523/jneurosci.18-23-10128.1998 (opens in a new tab)PepBankPUB-09822766
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats, MTII delivered to the fourth ventricle reduced short-term and 24 hour food intake in a dose-dependent way.

    In plain wordsIn rats, MTII given into the fourth brain ventricle lowered food intake, more so at higher doses.

    Peptide
    Melanotan II
    Outcome
    DecreaseFood intake after fourth-ventricle MTII
    Study

    ratn: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · fourth intracerebroventricularAs given in this study (rat).

    Source sentences

    Summary
    Fourth intracerebroventricular agonist treatment yielded a dose-dependent reduction of short-term (2 and 4 hr) and longer-term (24 hr) food intake and body weight.
    1 context sentence
    Summary · context
    MC-R agonist (MTII) and antagonist (SHU9119)
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats, MTII delivered to the fourth ventricle reduced body weight in a dose-dependent way.

    In plain wordsIn rats, MTII given into the fourth brain ventricle lowered body weight, more so at higher doses.

    Peptide
    Melanotan II
    Outcome
    DecreaseBody weight after fourth-ventricle MTII
    Study

    ratn: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · fourth intracerebroventricularAs given in this study (rat).

    Source sentences

    Summary
    Fourth intracerebroventricular agonist treatment yielded a dose-dependent reduction of short-term (2 and 4 hr) and longer-term (24 hr) food intake and body weight.
    1 context sentence
    Summary · context
    MC-R agonist (MTII) and antagonist (SHU9119)
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats, MTII delivered to the lateral ventricle gave dose-response effects on food intake comparable to fourth-ventricle delivery.

    In plain wordsIn rats, MTII given into the side brain ventricle lowered food intake in a similar way.

    Peptide
    Melanotan II
    Outcome
    DecreaseFood intake after lateral-ventricle MTII
    Study

    ratn: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · lateral intracerebroventricularAs given in this study (rat).

    Source sentences

    Summary
    Comparable dose-response functions for food intake and body weight were observed when these compounds were delivered to the lateral ventricle.
    2 context sentences
    Summary · context
    Fourth intracerebroventricular agonist treatment yielded a dose-dependent reduction of short-term (2 and 4 hr) and longer-term (24 hr) food intake and body weight.
    Summary · context
    MC-R agonist (MTII) and antagonist (SHU9119)
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats, MTII delivered to the lateral ventricle gave dose-response effects on body weight comparable to fourth-ventricle delivery.

    In plain wordsIn rats, MTII given into the side brain ventricle lowered body weight in a similar way.

    Peptide
    Melanotan II
    Outcome
    DecreaseBody weight after lateral-ventricle MTII
    Study

    ratn: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · lateral intracerebroventricularAs given in this study (rat).

    Source sentences

    Summary
    Comparable dose-response functions for food intake and body weight were observed when these compounds were delivered to the lateral ventricle.
    2 context sentences
    Summary · context
    Fourth intracerebroventricular agonist treatment yielded a dose-dependent reduction of short-term (2 and 4 hr) and longer-term (24 hr) food intake and body weight.
    Summary · context
    MC-R agonist (MTII) and antagonist (SHU9119)
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In food-deprived rats, MTII had no effect on weight loss.

    In plain wordsIn food-deprived rats, MTII did not change weight loss.

    Peptide
    Melanotan II
    Outcome
    No significant changeWeight loss in food-deprived rats after MTII
    Study

    ratn: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Results from deprived rats (no effect of MTII or SHU9119 on weight loss
    1 context sentence
    Summary · context
    MC-R agonist (MTII) and antagonist (SHU9119)

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.